ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, announced today that the first patient has been enrolled in the COMPLIANCE 360° clinical trial. This prospective, randomized study will generate additional data on patient outcomes achieved in treating lesions above the knee with CSI’s Diamondback 360°® Peripheral Arterial System, a minimally invasive catheter for treating peripheral arterial disease (PAD).
